Hommer_edit:Layout 1 27/08/2009 10:09 Page 22
Glaucoma
individuals, Ophthalmology, 2008;115:2030–36. 29. Strahlman E, Tipping R, Vogel R, A double-masked, patients switched from a combination of timolol and a
6. Gordon MO, Torri V, Miglior S, et al., Validated prediction randomized 1-year study comparing dorzolamide nonprostaglandin medication, Ophthalmology, 2006;113:
model for the development of primary open-angle (Trusopt), timolol, and betaxolol. International Dorzolamide 442–5.
glaucoma in individuals with ocular hypertension, Study Group, Arch Ophthalmol, 1995;113:1009–16. 48. Martinez A, Sanchez M, Bimatoprost/timolol fixed
Ophthalmology, 2007;114:10–19. 30. Bucci MG, Intraocular pressure-lowering effects of combination vs latanoprost/timolol fixed combination in
7. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al., latanoprost monotherapy versus latanoprost or open-angle glaucoma patients, Eye, 2009;23(4):810–18.
Predictive factors for glaucomatous visual field pilocarpine in combination with timolol: a randomized, 49. Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, et al.,
progression in the Advanced Glaucoma Intervention observer-masked multicenter study in patients with open- Concomitant administration of travoprost and
Study, Ophthalmology, 2004;111:1627–35. angle glaucoma. Italian Latanoprost Study Group, brinzolamide versus fixed latanoprost/timolol combined
8. The AGIS Investigators, The Advanced Glaucoma J Glaucoma, 1999;8:24–30. therapy: three-month comparison of efficacy and safety,
Intervention Study (AGIS): 7. The relationship between 31. Higginbotham EJ, Diestelhorst M, Pfeiffer N, et al., The Curr Med Res Opin, 2004;20:1333–9.
control of intraocular pressure and visual field efficacy and safety of unfixed and fixed combinations of 50. Choudhri S, Wand M, Shields MB, A comparison of
deterioration, Am J Ophthalmol, 2000;130:429–40. latanoprost and other antiglaucoma medications, Surv dorzolamide-timolol combination versus the concomitant
9. Collaborative Normal-Tension Glaucoma Study Group, The Ophthalmol, 2002;47(Suppl. 1):S133–40. drugs, Am J Ophthalmol, 2000;130:832–3.
effectiveness of intraocular pressure reduction in the 32. O’Connor DJ, Martone JF, Mead A, Additive intraocular 51. Strohmaier K, Snyder E, DuBiner H, et al., The efficacy and
treatment of normal-tension glaucoma, Am J Ophthalmol, pressure lowering effect of various medications with safety of the dorzolamide-timolol combination versus the
1998;126:498–505. latanoprost, Am J Ophthalmol, 2002;133:836–7. concomitant administration of its components.
10. Kass MA, Heuer DK, Higginbotham EJ, et al., The Ocular 33. Robin AL, Novack GD, Covert DW, et al., Adherence in Dorzolamide-Timolol Study Group, Ophthalmology,
Hypertension Treatment Study: a randomized trial glaucoma: objective measurements of once-daily and 1998;105:1936–44.
determines that topical ocular hypotensive medication adjunctive medication use, Am J Ophthalmol, 2007;144: 52. Diestelhorst M, Larsson LI, A 12-week, randomized,
delays or prevents the onset of primary open-angle 533–40. double-masked, multicenter study of the fixed
glaucoma, Arch Ophthalmol, 2002;120:701–13, discussion 34. Khouri AS, Realini T, Fechtner RD, Use of fixed-dose combination of latanoprost and timolol in the evening
829–30. combination drugs for the treatment of glaucoma, Drugs versus the individual components, Ophthalmology,
11. Heijl A, Leske MC, Bengtsson B, et al., Reduction of Aging, 2007;24:1007–16. 2006;113:70–76.
intraocular pressure and glaucoma progression: results 35. Dunker S, Schmucker A, Maier H, Tolerability, quality of life, 53. Hutzelmann J, Owens S, Shedden A, et al., Comparison of
from the Early Manifest Glaucoma Trial, Arch Ophthalmol, and persistency of use in patients with glaucoma who are the safety and efficacy of the fixed combination of
2002;120:1268–79. switched to the fixed combination of latanoprost and dorzolamide/timolol and the concomitant administration
12. Mills RP, Janz NK, Wren PA, et al., Correlation of visual field timolol, Adv Ther, 2007;24:376–86. of dorzolamide and timolol: a clinical equivalence study.
with quality-of-life measures at diagnosis in the 36. Diestelhorst M, Almegard B, Comparison of two fixed International Clinical Equivalence Study Group, Br J
Collaborative Initial Glaucoma Treatment Study (CIGTS), combinations of latanoprost and timolol in open-angle Ophthalmol, 1998;82:1249–53.
J Glaucoma, 2001;10:192–8. glaucoma, Graefes Arch Clin Exp Ophthalmol, 1998;236: 54. Konstas AG, Katsimpris IE, Kaltsos K, et al., Twenty-four-
13. Leske MC, Heijl A, Hussein M, et al., Factors for glaucoma 577–81. hour efficacy of the brimonidine/timolol fixed combination
progression and the effect of treatment: the early 37. Konstas AG, Boboridis K, Tzetzi D, et al., Twenty-four- versus therapy with the unfixed components, Eye,
manifest glaucoma trial, Arch Ophthalmol, 2003;121:48–56. hour control with latanoprost-timolol-fixed combination 2008;22:1391–7.
14. Miglior S, Zeyen T, Pfeiffer N, et al., Results of the therapy vs latanoprost therapy, Arch Ophthalmol, 2005;123: 55. Schuman JS, Katz GJ, Lewis RA, et al., Efficacy and
European Glaucoma Prevention Study, Ophthalmology, 898–902. safety of a fixed combination of travoprost 0.004%/timolol
2005;112:366–75. 38. Konstas AG, Lake S, Economou AI, et al., 24-Hour control 0.5% ophthalmic solution once daily for open-angle
15. Osborne NN, Recent clinical findings with memantine with a latanoprost-timolol fixed combination vs timolol glaucoma or ocular hypertension, Am J Ophthalmol,
should not mean that the idea of neuroprotection in alone, Arch Ophthalmol, 2006;124:1553–7. 2005;140:242–50.
glaucoma is abandoned, Acta Ophthalmol, 2009;87(4): 39. Olander K, Zimmerman TJ, Downes N, et al., Switching 56. Sherwood MB, Craven ER, Chou C, et al., Twice-daily 0.2%
450–54. from latanoprost to fixed-combination latanoprost-timolol: brimonidine-0.5% timolol fixed-combination therapy vs
16. Wan Z, Woodward DF, Cornell CL, et al., Bimatoprost, a 21-day, randomized, double-masked, active-control monotherapy with timolol or brimonidine in patients with
prostamide activity, and conventional drainage, Invest study in patients with glaucoma and ocular hypertension, glaucoma or ocular hypertension: a 12-month randomized
Ophthalmol Vis Sci, 2007;48:4107–15. Clin Ther, 2004;26:1619–29. trial, Arch Ophthalmol, 2006;124:1230–38.
17. Kastor JA (ed.), Arrhythmias, Philadelphia: WB Saunders Co, 40. European Latanoprost Fixed Combination Study Group, A 57. Buller AJ, Morgan LH, Hercules BL, Patients prefer once-
1994. comparison of the fixed combination of latanoprost and daily glaucoma drops, Graefes Arch Clin Exp Ophthalmol,
18. Charap AD, Shin DH, Petursson G, et al., Effect of varying timolol with its individual components, Secondary A 2007;245:293–4.
drop size on the efficacy and safety of a topical beta comparison of the fixed combination of latanoprost and 58. Nordstrom BL, Friedman DS, Mozaffari E, et al.,
blocker, Ann Ophthalmol, 1989;21:351–7. timolol with its individual components, Graefes Arch Clin Exp Persistence and adherence with topical glaucoma
19. Fraunfelder FT, Meyer SM, Systemic adverse reactions to Ophthalmol, 2002;240:893–9. therapy, Am J Ophthalmol, 2005;140:598–606.
glaucoma medications, Int Ophthalmol Clin, 1989;29:143–6. 41. Diestelhorst M, Larsson LI, A 12 week study comparing 59. Novack GD, O’Donnell MJ, Molloy DW, New glaucoma
20. Lama PJ, Systemic adverse effects of beta-adrenergic the fixed combination of latanoprost and timolol with the medications in the geriatric population: efficacy and
blockers: an evidence-based assessment, Am J Ophthalmol, concomitant use of the individual components in patients safety, J Am Geriatr Soc, 2002;50:956–62.
2002;134:749–60. with open angle glaucoma and ocular hypertension, Br J 60. Reardon G, Schwartz GF, Mozaffari E, Patient persistency
21. Vuori ML, Ali-Melkkila T, Kaila T, et al., Beta 1- and beta Ophthalmol, 2004;88:199–203. with topical ocular hypotensive therapy in a managed
2-antagonist activity of topically applied betaxolol and 42. Konstas AG, Banyai L, Blask KD, et al., Intraocular pressure care population, Am J Ophthalmol, 2004;137:S3–12.
timolol in the systemic circulation, Acta Ophthalmol (Copenh), and safety in glaucoma patients switching to 61. Reardon G, Schwartz GF, Mozaffari E, Patient persistency
1993;71:682–5. latanoprost/timolol maleate fixed combination from with ocular prostaglandin therapy: a population-based,
22. Zimmerman TJ, Baumann JD, Hetherington J, Jr., mono- and adjunctive therapies, J Ocul Pharmacol Ther, retrospective study, Clin Ther, 2003;25:1172–85.
Side effects of timolol, Surv Ophthalmol, 1983;28(Suppl.): 2004;20:375–82. 62. Parrish RK, Palmberg P, Sheu WP, A comparison of
243–51. 43. Konstas AG, Kozobolis VP, Lallos N, et al., Daytime diurnal latanoprost, bimatoprost, and travoprost in patients with
23. Kirwan JF, Nightingale JA, Bunce C, et al., Beta blockers for curve comparison between the fixed combinations of elevated intraocular pressure: a 12-week, randomized,
glaucoma and excess risk of airways obstruction: latanoprost 0.005%/timolol maleate 0.5% and dorzolamide masked-evaluator multicenter study, Am J Ophthalmol,
population based cohort study, BMJ, 2002;325:1396–7. 2%/timolol maleate 0.5%, Eye, 2004;18:1264–9. 2003;135:688–703.
24. Schoene RB, Martin TR, Charan NB, et al., Timolol-induced 44. Shin DH, Feldman RM, Sheu WP, Efficacy and safety of the 63. Honrubia F, Garcia-Sanchez J, Polo V, et al., Conjunctival
bronchospasm in asthmatic bronchitis, JAMA, 1981;245: fixed combinations latanoprost/timolol versus hyperaemia with the use of latanoprost versus other
1460–61. dorzolamide/timolol in patients with elevated intraocular prostaglandin analogues in patients with ocular
25. Van Buskirk EM, Adverse reactions from timolol pressure, Ophthalmology, 2004;111:276–82. hypertension or glaucoma: a meta-analysis of randomised
administration, Ophthalmology, 1980;87:447–50. 45. Garcia-Sanchez J, Rouland JF, Spiegel D, et al., A clinical trials, Br J Ophthalmol, 2009;93:316–21.
26. van der Valk R, Webers CA, Schouten JS, et al., Intraocular comparison of the fixed combination of latanoprost and 64. Schwartz GF, Reardon G, Mozaffari E, Persistency with
pressure-lowering effects of all commonly used glaucoma timolol with the unfixed combination of brimonidine and latanoprost or timolol in primary open-angle glaucoma
drugs: a meta-analysis of randomized clinical trials, timolol in patients with elevated intraocular pressure. A suspects, Am J Ophthalmol, 2004;137:S13–16.
Ophthalmology, 2005;112:1177–85. six month, evaluator masked, multicentre study in Europe, 65. Reardon G, Schwartz GF, Mozaffari E, Patient persistency
27. Hollo G, The side effects of the prostaglandin analogues, Br J Ophthalmol, 2004;88:877–83. with pharmacotherapy in the management of glaucoma,
Expert Opin Drug Saf, 2007;6:45–52. 46. Stewart WC, Stewart JA, Day D, et al., Efficacy and safety Eur J Ophthalmol, 2003;13(Suppl. 4):S44–52.
28. Schuman JS, Horwitz B, Choplin NT, et al., A 1-year study of timolol maleate/latanoprost fixed combination versus 66. Hamacher T, Schinzel M, Scholzel-Klatt A, et al., Short term
of brimonidine twice daily in glaucoma and ocular timolol maleate and brimonidine given twice daily, Acta efficacy and safety in glaucoma patients changed to the
hypertension. A controlled, randomized, multicenter Ophthalmol Scand, 2003;81:242–6. latanoprost 0.005%/timolol maleate 0.5% fixed
clinical trial. Chronic Brimonidine Study Group, Arch 47. Magacho L, Reis R, Shetty RK, et al., Efficacy of combination from monotherapies and adjunctive
Ophthalmol, 1997;115:847–52. latanoprost or fixed-combination latanoprost-timolol in therapies, Br J Ophthalmol, 2004;88:1295–8.
22 EUROPEAN OPHTHALMIC REVIEW